CytomX Therapeutics (STU:6C1) Change In Receivables : €0.4 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Change In Receivables?

CytomX Therapeutics's change in receivables for the quarter that ended in Dec. 2024 was €0.2 Mil. It means CytomX Therapeutics's Accounts Receivable declined by €0.2 Mil from Sep. 2024 to Dec. 2024 .

CytomX Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was €0.3 Mil. It means CytomX Therapeutics's Accounts Receivable declined by €0.3 Mil from Dec. 2023 to Dec. 2024 .

CytomX Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was €3.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. CytomX Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2024 was 7.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CytomX Therapeutics's liquidation value for the three months ended in Dec. 2024 was €-17.2 Mil.

CytomX Therapeutics Change In Receivables Historical Data

The historical data trend for CytomX Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Change In Receivables Chart

CytomX Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-0.65

0.01

-33.23

29.85

0.31

CytomX Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-0.93	-8.97	9.66	-0.52	0.24

CytomX Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.4 Mil.

CytomX Therapeutics (STU:6C1) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CytomX Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.963	/	36.379	*	91
=	7.43

2. In Ben Graham's calculation of liquidation value, CytomX Therapeutics's accounts receivable are only considered to be worth 75% of book value:

CytomX Therapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	96.095	-	115.544	+	0.75 * 2.963	+	0.5 * 0
=	-17.2

CytomX Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines